We propose that the miR-509-3p/AXL and miR-509-3p/ARHGAP1 axes could be used to discover new druggable targets to significantly reverse chemo-resistance and inhibit cellular migration/invasion of cell from the primary tumor, thus leading to improved clinical outcomes for patients presenting with metastatic OS. Here, ARHGAP1 is linked to neoplasm.